Skip to main content
S&P 5007,712.64-1.19%DOW51,472.69-0.38%NASDAQ26,713.04-1.81%BTC$81,769.00-1.65%ETH$2,435.88-2.69%GOLD$4,107.30-1.68%OIL$95.60+1.55%
Smart Investors Daily
SID Premium
Bristol-Myers Squibb Company logo

NASDAQ · BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

$56.67

Up+$1.95 (+3.44%)

Updated Oct 14, 2026, 4:57 PM

SID Score

5.6/10

Composite research score

Smart Money

50/100

Neutral

Market cap
104.23B
P/E ratio
17.28
Dividend yield
4.38%
52-week range
$52.06 – $68.64
Volume
16.96M
Avg. volume
16.54M

Price performance · BMY

BMY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 13, 2026

BMY closed at $56.67 after 21 trading sessions, down 11.08% for the selected period.

Last close
$56.67
Period change
-11.08%
Period low
$56.67
Period high
$63.88
Daily close
View OHLC price history
BMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 13, 2026$57.775$58.0242$56.15$56.6716.96M
Oct 12, 2026$60.11$60.68$56.72$57.5822.57M
Oct 9, 2026$58.88$59.79$58.74$59.129.25M
Oct 8, 2026$59.10$59.94$58.73$59.5813.07M
Oct 7, 2026$59.45$60.10$59.01$59.7011.09M
Oct 6, 2026$58.94$59.595$58.635$59.599.89M
Oct 5, 2026$59.89$60.15$58.33$58.8119.24M
Oct 2, 2026$60.66$61.24$60.24$61.159.94M
Oct 1, 2026$62.20$62.61$61.25$61.4610.77M
Sep 30, 2026$63.275$64.13$62.40$62.4015.87M
Sep 29, 2026$63.58$63.89$61.95$62.8615.84M
Sep 28, 2026$62.77$63.93$62.30$63.8814.02M
Sep 25, 2026$61.75$62.91$61.395$62.8610.67M
Sep 24, 2026$61.40$61.59$60.595$61.5014.9M
Sep 23, 2026$62.31$62.65$61.075$61.1515.84M
Sep 22, 2026$62.73$63.08$62.03$62.2515.24M
Sep 21, 2026$63.09$63.395$62.62$62.626.84M
Sep 18, 2026$62.71$63.065$62.19$63.0636.85M
Sep 17, 2026$64.08$64.35$62.52$62.8412.21M
Sep 16, 2026$64.07$64.385$63.22$63.609.45M
Sep 15, 2026$63.94$64.13$63.15$63.7310M

Latest BMY news

The latest Smart Investors Daily articles mentioning BMY.

Stock researchCompany · Overview

BMY research

Overview

Company profile and research snapshot.

Company profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.25
Implied upside
—
Analysts
17
BMY recent ratings
DateFirmRatingTarget
Oct 13, 2026Wells FargoEqual-Weight—
Oct 8, 2026Cantor FitzgeraldNeutral—
Oct 7, 2026Morgan StanleyUnderweight—
Oct 5, 2026Leerink PartnersMarket Perform—
Sep 16, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

What Could Bristol Myers Squibb (BMY) Phase 3 Myeloma Data Mean For Investors?

Bristol Myers Squibb (NYSE:BMY) reported new Phase 3 EXCALIBER-RRMM data for its Zenbexus combination in relapsed or refractory multiple myeloma. The regimen achieved significant progression free survival in the trial, alongside high minimal residual disease negative complete response rates. EXCALIBER-RRMM results are being positioned as supportive evidence for potential accelerated approval of Zenbexus in this blood cancer setting. The strong progression free survival and MRD negative...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By